Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

May 08, 2025 09:00 ET | Source: Dogwood Therapeutics, Inc.

Dogwood Therapeutics Announces First Quarter 2025 Financial Results

- Dogwood Therapeutics, Inc. commenced dosing of patients in the Halneuron® Chemotherapy Induced Neuropathic Pain Phase 2b Study - - Halneuron® Chemotherapy Induced Neuropathic Pain Phase 2b study...
March 31, 2025 15:45 ET | Source: Dogwood Therapeutics, Inc.

Dogwood Therapeutics Announces Fourth Quarter and Full Year 2024 Financial Results

-Dogwood Therapeutics, Inc. commenced dosing of patients in the Halneuron® Chemotherapy Induced Neuropathic Pain (“CINP”) Phase 2b Trial - - Halneuron® CINP P2b study interim data readout is expected...
March 18, 2025 08:45 ET | Source: Dogwood Therapeutics, Inc.

Dogwood Therapeutics Announces Dosing of First Patient in Phase 2b Trial Evaluating Halneuron® in Patients with Chemotherapy-Induced Neuropathic Pain

ATLANTA, March 18, 2025 (GLOBE NEWSWIRE) -- Dogwood Therapeutics, Inc. (Nasdaq: DWTX) (“Dogwood” or the “Company”), a development-stage biopharmaceutical company focused on advancing first-in-class,...
September 15, 2021 20:30 ET | Source: Psychable, Inc.

Pain Awareness Month: Psychable Educates Patients on Transformative Power of Using Psychedelics as Medicine for Pain Treatment, Management and Healing

LOS ANGELES, Sept. 15, 2021 (GLOBE NEWSWIRE) -- September is Pain Awareness Month. Affecting more than 50 million Americans, chronic pain - both unmanaged and unmanaged, physical and emotional - is...